Compare Novavax Inc (NVAX) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Health Care Select Sector SPDR Fund — how do they compare? Novavax Inc trades at $12.7 (market cap $1.82B), while Health Care Select Sector SPDR Fund trades at $170.85 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 23.9× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Health Care Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| NVAX | XLV | |
|---|---|---|
Market Cap | $1.82B | $43.48B |
Volume | 6,198,505 | 11,121,431 |
Sector | Health | — |
52-Week High | $12.56 | $175.68 |
52-Week Low | $6.22 | $141.95 |
Typical Hold Time | 59 Days | 100 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
XLV trades at $170.86, up 1.21% with a bearish technical signal from moving averages while oscillators remain neutral. The healthcare ETF shows strong cost advantages with a 0.08% expense ratio compared to peers, holding 61 diversified healthcare stocks from the S&P 500. Recent news highlights XLV's defensive characteristics during potential Fed rate hikes and political volatility.
The ETF offers defensive exposure to healthcare with low costs, though technical indicators suggest near-term pressure. Key risks include sector-specific regulatory changes and election uncertainty, while the fund's diversification provides stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
